Repligen (NASDAQ:RGEN) Given New $185.00 Price Target at Wells Fargo & Company

Repligen (NASDAQ:RGEN) had its price target lifted by stock analysts at Wells Fargo & Company from $180.00 to $185.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s target price indicates a potential upside of 30.26% from the stock’s previous close.

RGEN has been the subject of a number of other reports. Barclays increased their target price on shares of Repligen from $145.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a report on Tuesday, July 7th. Evercore reaffirmed an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a research note on Monday, July 6th. Rothschild & Co Redburn set a $160.00 price objective on Repligen and gave the stock a “buy” rating in a report on Friday, April 17th. Finally, Royal Bank Of Canada initiated coverage on Repligen in a report on Thursday, May 14th. They set an “outperform” rating and a $160.00 price objective for the company. Two investment analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $166.43.

Repligen Price Performance

Shares of NASDAQ:RGEN traded up $0.80 on Thursday, reaching $142.03. 122,129 shares of the company were exchanged, compared to its average volume of 1,016,458. The company has a 50-day moving average of $133.54 and a 200-day moving average of $131.70. The company has a current ratio of 9.05, a quick ratio of 7.78 and a debt-to-equity ratio of 0.26. The firm has a market cap of $8.01 billion, a price-to-earnings ratio of 194.43, a price-to-earnings-growth ratio of 2.80 and a beta of 1.06. Repligen has a 1-year low of $100.99 and a 1-year high of $175.77.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. The firm had revenue of $204.13 million during the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter last year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts forecast that Repligen will post 1.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In related news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. The trade was a 3.65% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Repligen

A number of large investors have recently bought and sold shares of the stock. Bayforest Capital Ltd purchased a new position in Repligen during the fourth quarter worth $32,000. Rachor Investment Advisory Services LLC purchased a new stake in shares of Repligen in the fourth quarter valued at $33,000. Measured Wealth Private Client Group LLC purchased a new stake in shares of Repligen in the third quarter valued at $29,000. Los Angeles Capital Management LLC acquired a new stake in shares of Repligen during the fourth quarter valued at $36,000. Finally, Farther Finance Advisors LLC boosted its stake in shares of Repligen by 61.8% during the fourth quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 128 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Key Stories Impacting Repligen

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q2 earnings beat expectations: Repligen reported revenue of approximately $204.1 million, up 11.9% year over year and ahead of the $201.6 million consensus estimate. Adjusted earnings per share reached $0.54, surpassing expectations of $0.45 and more than doubling the prior-year figure. Repligen Beats Q2 Earnings Estimates, Raises 2026 View
• Positive Sentiment: Raised 2026 guidance: Management increased its organic revenue-growth outlook to 10.5%-13.5% and raised adjusted EPS guidance to $2.03-$2.09. The company also cited stronger orders, improving second-half visibility and broad-based demand across key product lines. Repligen jumps after Q2 beat and higher 2026 outlook
• Positive Sentiment: JPMorgan raised its price target: JPMorgan increased its target from $165 to $175 while maintaining an Overweight rating, signaling confidence that earnings momentum can support further upside. JPMorgan price target report
• Positive Sentiment: BioLife Solutions acquisition viewed as a potential growth driver: Management characterized the pending transaction as supportive of long-term revenue growth, margin expansion and earnings accretion. Repligen held an M&A call with BioLife Solutions
• Neutral Sentiment: Valuation remains demanding: Canaccord Genuity maintained a Hold rating and $145 price target, noting that strong operating momentum is substantially reflected in the stock’s valuation. Repligen valuation and analyst rating
• Negative Sentiment: Recent insider activity has been limited to sales: Chief Executive Officer Olivier Loeillot and CFO Jason Garland sold shares during the past six months, which may provide a modest cautionary signal but does not directly change the company’s operating outlook.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.